Page 5 - Johan Dalsgaard News Today

Webinar On Thursday, September 30 @ 16:00 CET (10AM ET) With The Medical Doctors And IPF Experts Prof. Toby Maher and Prof. Joanna Porter. GOTHENBURG, Sweden, Sept. 22, 2021 /PRNewswire/

STOCKHOLM, Aug. 26, 2021 /PRNewswire/ -- Important events during the second quarter In May, Vicore1 announced that it had entered into a collaboration agreement with Alex Therapeutics

STOCKHOLM, Aug. 26, 2021 /PRNewswire/ -- Important events during the second quarter In May, Vicore1 announced that it had entered into a collaboration agreement with Alex Therapeutics

/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders...

318.7 1 There is no dilution effect for potential ordinary shares for periods where earnings have been negative. 2 Alternative performance measure (APM). Defined on page 20 in the interim report. CEO Comments The first quarter of 2021 has been very productive for Vicore continuing to build on the clinical success achieved with C21 in 2020. In the beginning of February, the company raised 336 MSEK (approx. 40 MUSD) in a directed share issue that attracted Swedish and international institutional...

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF - Webinar will be held today at 15:00 CET (9:00 am EST) - Digital therapeutics expert Jessica Shull joins Vicore to drive DTx program News provided by Share this article GOTHENBURG, Sweden, May 4, 2021 /PRNewswire/ --  Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary ...

Share this article GOTHENBURG, Sweden, April 20, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announced that it will host a key opinion leader (KOL) webinar on C21, the companys lead asset for the treatment of COVID-19, on Wednesday, April 28, 2021 at 14:00 CET (8 am EST). The event will feature a presentation by KOL Professor Maureen Horton,...

Vicore Pharmas drug candidate C21 dilates peripheral resistance vessels in fibrotic disease News provided by Share this article GOTHENBURG, Sweden, March 11, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces top line data from a phase II study of its oral angiotensin II type 2 receptor (AT2R) agonist C21 in patients with systemic sclerosis and Rayn...

Vicore Pharma intends to carry out a directed share issue GOTHENBURG, Sweden, Feb. 9, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore Pharma" or the "Company") today announces its intention to carry out a directed share issue corresponding to approximately SEK 300 million to institutional investors through an accelerated bookbuilding procedure (the "Directed New Share Issue"). The Directed New Share Issue is intended to be carried out through an accelerated bookbuilding procedure...

Share this article GOTHENBURG, Sweden, Feb. 1, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, today published data from the phase II study ATTRACT online and submitted it to a peer reviewed journal. The results show restoration of lung function in COVID-19 on top of corticosteroids and remdesivir with the companys oral drug C21, suggesting that C21 can become an important complement to vacci...